Mirum Pharmaceuticals Q2 2025 Earnings Preview: EPS Estimate $-0.33, Revenue Estimate $108.1M.

Mirum Pharmaceuticals is set to announce Q2 2025 earnings results on August 6th. The consensus EPS estimate is -$0.33, a 36.5% YoY increase, while the revenue estimate is $108.1M, a 38.9% YoY increase. Over the past year, Mirum's stock has seen significant growth.

Mirum Pharmaceuticals, Inc. (MIRM) is poised to release its Q2 2025 earnings results on August 6th, with investors eagerly awaiting the company's performance. The consensus EPS estimate stands at -$0.33, reflecting a year-over-year increase of 36.5%. Revenue estimates are projected to reach $108.1 million, a 38.9% increase from the same period last year.

Analysts have revised their estimates upward, with the consensus EPS estimate increasing by 6.92% over the last 30 days. This upward revision suggests analysts have become more optimistic about the company's earnings prospects. The Most Accurate Estimate is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +8.65%. This positive Earnings ESP, combined with Mirum Pharmaceuticals' Zacks Rank of #3, indicates a strong likelihood of beating the consensus EPS estimate.

Historically, Mirum Pharmaceuticals has shown a track record of beating consensus EPS estimates. In the last reported quarter, the company delivered a surprise of +23.08%, surpassing expectations. Over the past four quarters, Mirum Pharmaceuticals has beaten consensus EPS estimates two times.

While earnings surprises can significantly impact stock prices, other factors may also influence Mirum Pharmaceuticals' stock performance. Investors should consider the broader market conditions and the company's strategic initiatives when evaluating the potential impact of the earnings report.

Mirum Pharmaceuticals has seen significant stock growth over the past year, and the upcoming earnings report will be a crucial indicator of the company's continued trajectory. Investors should stay tuned for the earnings announcement and management's discussion of business conditions to gain further insights into the company's future prospects.

References:
[1] https://finance.yahoo.com/news/mirum-pharmaceuticals-inc-mirm-expected-140037412.html
[2] https://www.nasdaq.com/articles/mirum-pharmaceuticals-inc-mirm-expected-beat-earnings-estimates-what-know-ahead-q2-release